Physician profile
Jon M Moore
NPI 1568429462
$27,566.08
in general payments reported to CMS, 2019-2025
28 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what 85% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $4,349 · 2021: $385 · 2022: $2,487 · 2023: $793 · 2024: $1,547 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $750 · Travel and Lodging: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $750.00 |
| Travel and Lodging | $330.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $23,592.41 | 2019-2025 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $1,288.36 | 2019 | |
| Davol INC. | $972.96 | 2019-2025 | Phasix Mesh |
| Tela Bio, INC. | $382.94 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Ethicon US, LLC | $269.63 | 2019-2024 | Echelon Endopath, Echelon Flex |
| Merck Sharp & Dohme LLC | $143.45 | 2019-2020 | |
| Baxter Healthcare | $120.36 | 2019-2020 | |
| Mimedx Group, INC. | $109.61 | 2024-2025 | |
| Conmed Corporation | $64.78 | 2024-2025 | Airseal |
| Regeneron Healthcare Solutions, INC. | $53.72 | 2023 | Libtayo |
| Abbott Laboratories | $51.55 | 2022-2025 | Eterna |
| Biocomposites INC | $48.07 | 2024 | |
| Zimvie INC. | $47.40 | 2022-2023 | |
| Si-Bone, INC. | $46.07 | 2021-2024 | |
| Kerecis Limited | $45.51 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $40.14 | 2023 | Tymlos |
| Boston Scientific Corporation | $36.52 | 2024 | Wavewriter Alpha Prime 16 |
| Shire North American Group INC | $35.24 | 2019 | |
| Genzyme Corporation | $33.38 | 2019-2022 | |
| Merit Medical Systems INC | $32.79 | 2020-2021 | |
| Medtronic, INC. | $30.12 | 2021-2024 | Ligasure |
| Solventum Corporation | $21.98 | 2024 | Prevena, V.A.C. Veraflo |
| Acell, INC. | $19.58 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.12 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.87 | 2022 | |
| Hologic Sales and Service, LLC | $15.76 | 2025 | Sentimag |
| Integra Lifesciences Corporation | $15.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.